The CDTI SICC Innvierte of Innovation invests, together with four coinversores deepull, in order to accelerate the diagnosis of sepsis

Sepsis cause or contribute directly to 1 in 3 hospital deaths in the usa and septic shock has a mortality rate of 30-40 per cent globally. The difficulty of identifying infections in the bloodstream and treat septicaemia is widely documented, since the early diagnosis is a major challenge due to the symptoms are non-specific and difficult to identify.

The current standard diagnoses used hemocultivos sepsis that can take days to produce results and often fail to identify pathogens in patients suspected of having sepsis.

The medical technology company that develops deepull diagnostic solutions without cultivation for the rapid identification of pathogens in total blood, develops a test that will identify the cause of a potential sepsis, about one hour.

In order to finance this research, this company has closed a funding round in which, inter alia, the CDTI Innovation, through Innvierte coinversores together with the HIGH Life Sciences Spain I, RCF; Columbus Life Sciences Fund IV, RCF; Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR, SA.

The input committed by the CDTI innovation is 9.999.756,15 euros.

deepull

deepullit is a company in medical diagnostic without develops solutions for diagnostic sepsis and infections agudas. deepull is developing proof UllCORE BSI, capable of detecting the 95% of pathogens that cause septicaemia. The DNA evidence extracted microbial 8 mL of blood and provides total 52 results. The test is carried out in the analyzer UllCORE of deepull; a system with total automation designed to meet the needs of any clinical laboratory hospitable.

AltamarCAM Partners

AltamarCAM Partnersit is an independent operator of private assets that provides solutions to their investors, with more than €20,800 million in assets under management. One of its programmes of investment is high Life Sciences Spain I RCF, focused on investment in biotechnology, Biopharmacy, Medical devices/diagnostics, Genomics and Digital health, and managed with the advice of Aliath Bioventures team.

Columbus Venture Partners,

Columbus Venture Partners,is a spanish venture capital oriented towards the development and promotion of businesses that emerge in a sector of tracks, such as biotechnology and health sciences. Columbus VP intends to launch Agile funds to invest in the field of biotechnology, with a 50 per cent in therapies and 50 per cent in industrial development. One of these funds is Columbus Life Sciences Fund IV, RCF, with a target size of 150 million euros.

Asabys Partners

Asabys Partnersit is a venture capital firm specialized in the health sector, founded in 2018 by Josep Ll. Sanfeliu and clear, shared by Campàs Alantra and with the support of Banc Sabadell as anchor. Asabys investor invests in innovative companies and disruptive covering medical needs not covered in the vertical biofarma and health. Investment in the company comes from their vehicles Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR SA.

Innvierte

Innvierteit is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI Innovation, through Innvierte, committed 1.875 M €in 55 investment vehicles that have invested in more than 599 companies, and through its joint investment line directly committed an amount of 601 M €in 178 companies.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.
 

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.
 

More information:

Office of the press

prensa@cdti.es

91-581.55.00

On The Internet

Website:www.cdti.es

In Linkedin:https :// www.linkedin.com/company/29815

X:https :// twitter.com/CDTI _ innovation

On Youtube:https :// www.youtube.com/user/CDTIoficial

AltamarCAM Partners:

Website:https :// www.altamarcam.com/en/products/alta-life-sciences-spain-i-fcr-3/

In LinkedIn:https :// www.linkedin.com/company/altamarcam/

Columbus Life Sciences Fund IV, RCF:

Website:https :// columbusvp.com/

In LinkedIn:https :// www.linkedin.com/company/columbus-ventue-partners-s.g.e.i.c.-s.a/

X:https :// x.com/columbus _ vp

Asabys Partners:

Website:https :// asabys.com/

In LinkedIn:https :// www.linkedin.com/company/asabys-partners/

X:https :// x.com/AsabysPartners

deepull:

Website:www.deepull.com

In LinkedIn:https :// www.linkedin.com/company/deepull/

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).